Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.40 |
| ▸ | HTT | P42858 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532303 | 0.80 | MEN1 (0.43) | NPSR1HTTLMNATSHRSMN1; SMN2 | |
| SCHEMBL739241 | 0.78 | MEN1 (0.40) | HTTLMNATSHRSMN1; SMN2MEN1 | |
| SCHEMBL532611 | 0.77 | NPSR1 (0.37) | NPSR1HTTLMNATSHRSMN1; SMN2 | |
| SCHEMBL739017 | 0.71 | ATM (0.43) | NPSR1HTTLMNASMN1; SMN2MEN1 | |
| SCHEMBL736536 | 0.71 | CYP1A2 (0.45) | MEN1KMT2AATM | |
| SCHEMBL7086962 | 0.70 | PRSS1 (0.39) | MEN1KMT2A | |
| SCHEMBL16783177 | 0.68 | DAGLA (0.50) | LMNATSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20985875 | 0.68 | ATM (0.46) | SMN1; SMN2KMT2ADAGLAALDH1A1ATM | |
| SCHEMBL13859223 | 0.68 | MEN1 (0.51) | HTTLMNAMEN1KMT2APOLB | |
| SCHEMBL737633 | 0.65 | MEN1 (0.49) | HTTLMNAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138177-B2 | Benzimidazolone derivatives as CB2 receptor ligands | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | ANDO KAZUO | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181957-A1 | BENZIMIDAZOLONE DERIVATIVES AS CB2 RECEPTOR LIGANDS | TRPV1, CNR1, CNR2 | NPSR1 30/4885HTT 3298/4885LMNA 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.